GLMD
NASDAQ · Biotechnology
Galmed Pharmaceuticals Ltd
$0.66
+0.07 (+11.58%)
Open$0.61
Previous Close$0.60
Day High$0.68
Day Low$0.59
52W High$16.48
52W Low$11.93
Volume—
Avg Volume670.8K
Market Cap3.64M
P/E Ratio28.49
EPS$0.47
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,498.3% upside
Current
$0.66
$0.66
Target
$17.25
$17.25
$9.83
$17.25 avg
$23.67
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.77M | 1.41M |
| Net Income | 137.6K | 142.0K | 102.7K |
| Profit Margin | 8.1% | 8.0% | 7.3% |
| EBITDA | 176.3K | 217.6K | 150.4K |
| Free Cash Flow | 176.3K | 155.0K | 130.1K |
| Rev Growth | +12.1% | -7.4% | -2.7% |
| Debt/Equity | 1.54 | 1.34 | 1.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |